Boryung and Abbott has set co-marketing for the pancreatic enzyme preparations ‘Creon’

Published: 2014-12-03 13:54:32

Updated: 2014-12-03 14:14:55

Boryung and Abbott Korea will advance on co-marketing for ‘Creon’, an alternative drug for pancreatic exocrine dysfunction.

Boryung (president Tae-hong Choi)and Abbott Korea (president Yu-suk Jung) announced on the 1^st that they made a contract for co-marketing of ‘Creon’, which is aneffective pancreatic enzyme alternative drug for pancreatic exocrine dysfunction.

Under the contract between t...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.